Join
Live feed
·
INSIDERFilingvia Quantisnow
AIM ImmunoTech Inc. logo

CEO & President Equels Thomas K converted options into 25,000 shares, increasing direct ownership by 64% to 63,922 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
AIM· AIM ImmunoTech Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AIM (AIM ImmunoTech Inc.) and more on Quantisnow.